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1. Introduction 
1.1  Classification, epidemiology and cause of preterm birth 
Preterm birth (PTB) is defined by WHO (1976) as the births before 37 weeks of gestation or 
fewer than 259 days since the first day of last menstrual period of a women. PTB is the major 
cause of neonatal morbidity and mortality, which has been not reduced over the past 20-30 
years despite intensive antenatal and postnatal care programs, the comprehensive 
administration of tocolytics, and a series of preventive and therapeutic interventions. The 
exact causes of PTB are still unknown. Several risk factors for PTB have been reported: 
previous low birth weight or preterm delivery, repeated second trimester abortion, uterine and 
cervical abnormalities, in vitro fertilization, multiple pregnancy, maternal chronic medical 
conditions (e.g. diabetes, hypertension, anaemia, asthma, thyroid diseases), periodontal 
diseases, gestational bleeding, abnormal placentation, urinary tract infection, social and 
environmental status, smoking, alcohol consumption, maternal low body mass index (BMI) 
and genetic risk  (Moutquin 2003, Haas 2006, Pennell et al. 2007, Blencowe et al. 2013). 
Bacterial vaginosis, HIV and syphilis are also associated with a higher incidence of PTB 
(Gravett et al. 2010). Other factors including maternal age, parity, drug abuse, heredity, sexual 
activities, excessive physical workload, stress, inadequate prenatal care, and maternal weight 
gain are still misjudged (Berkowitz et al. 1998, Muglia and Katz 2010). The mortality rate of 
preterm babies increases with decreasing gestational age. Preterm births account for 70% of 
neonatal deaths and more than 75 % of the preterm infants, who are born alive, suffer from 
cerebral palsy, sensory deficits, neuro-inflammation, learning disabilities and respiratory 
diseases in later life compared with children born at term; resulting in enormous physical, 
psychological and economic costs (Petrou et al. 2003 and 2005, Papatsonis 2005). 
1.2  Tocolytic therapy 
PTB is the central problem in obstetrics and the principal risk factor for perinatal morbidity 
and mortality. Several agents are used for the tocolytic therapy such as magnesium sulfate; 
prostaglandin inhibitors (e.g.  indomethacin, ketorolac); nitrates (e.g. nitroglycerine); β-
mimetics (e.g. ritodrine, terbutaline); calcium channel blockers (e.g. nifedipine); oxytocin 
receptor blockers (e.g. atosiban), and progesterone. but there are many controversies in 
establishing efficacy and safety of the treatment (Kim et al. 2006, Witcher 2002). 
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Furthermore, these agenst are not able to reduce the frequencies of preterm birth within 2-7 
days and are not effective for the improvements of newborn mortality and morbidity. 
Magnesium sulphate plays an essential role in glycolysis, oxidative phosphorylation, protein 
synthesis and membrane integrity (Pasternak et al. 2010). The exact mechanism of action of 
magnesium sulphate as a tocolytic agent is partially known and controversial. It has been 
proposed that magnesium is able to modulate the calcium uptake and bind to the smooth 
muscle cells, thereby regulates multiple intracellular pathways (Mohan et al. 2006). Crowther 
et al. (2014) reported that magnesium sulphate had no effect for preventing PTB. Furthermore 
applying of magnesium sulphate is associated with the increased risk of newborn mortality. 
Intravenous magnesium administration can cause peripheral vasodilation, and the maternal 
side effects involves in nausea, vomiting, headache and palpitations. In higher dose (over the 
recommended therapeutic concentration), magnesium sulphate can lead to respiratory failure, 
hypotension, heart block and cardiac arrest (Kumar et al. 2013). 
Prostaglandins play an important role in the uterine contraction by resulting an increase of 
intracellular Ca level and contributing to the activation of myosin light chain kinase (Asboth 
et al. 1996). COX enzymes regulate the production of PG, therefore inhibiton of COX activity 
lead to a decreased level of PG and reduced uterine activity. Indomethacin, that ables to 
binding to COX reversibly, is a frequently used drug for tocolysis. Despite the favourable 
results, several studies have limited the use of indometacin because of the development of 
neonatal adverse effects including oligohydramnios, increased risk of ductus arteriosus 
closure, necrotizing enterocolitis and renal failure (Norton et al. 1993); and maternal adverse 
effects such as gastric ulcer and asthma (Caritis 2005). 
Nitric oxide (NO) is a forceful vasodilatator and present in myometrial cells. NO increases 
cyclic guanosine monophoshate (cGMP) and protein kinase (PK) G levels, thereby promote 
uterine relaxation. It was reported contradictory results of effectivity of NO donors. The 
results of the transdermal nitroglycerin administration showed better tocolytic effects than 
placebo and it was found out that nitroglycerin able to delay delivery for two days (Hubinont 
and Debiève 2011). According to the results of five randomized controlled trials, nitroglycerin 
did not delay labour and not improve neonatal outcome compared to placebo or alternative 
tocolytic (Arrowsmith 2010). 
The most commonly used drugs for the treatment of preterm labour are the betamimetics. 
Ritodrine and terbutaline were introduced as selective β2-adrenoceptor (ADRB2) agonists and 
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ritodrine hydrochloride was approved for use in preterm labour from 1980. β2-AR agonists 
able to reduce the intracellular cyclic adenosine monophosphate (cAMP) concentration and 
promote the myometrial relaxation based on randomised controlled trials and several 
subsequent meta-analyses. β2-AR agonists were more effective than placebo for delaying 
preterm labour for two days, but there have no beneﬁt for long-term treatment and perinatal 
mortality and morbidity rate (Anotayanonth et al. 2004). Unfortunately, it was reported 
signiﬁcant maternal side eﬀects associated with the administration of β2-AR agonists is 
tachycardia, dyspnoea, hypokalemia, hyperglycemia, and chest pain.  
Oxytocin receptor antagonists (atosiban, barusiban, epelsiban and retosiban) able to 
completely inhibit the uterotonic action of oxytocin in a competitive and dose-dependent 
manner and to downregulate oxytocin receptors and to inhibit oxytocin-mediated 
prostaglandin synthesis (Bernal 2007). Atosiban was the first drug which was directly 
developed to manage PTB and the only drug which is used in clinical practice. Three 
multinational, multicentre, double-blind, randomised, controlled trials was reported that 
atosiban had similar tocolytic effect and it was associated with fewer maternal cardiovascular 
side effects comparison to the conventional beta-agonist therapy (Worldwide Atosiban versus 
Beta‐agonists Study Group 2001) even so there is still controversy about its effectiveness and 
long-term safety (Witcher 2002).  
Supplemental treatment with progesterone (P) has been reported to prevent preterm labour 
(PTL) and birth (Meis et al. 2003, Fonseca et al. 2003). Progesterone is an essential steroid 
hormone which was secreted by the corpus luteum and by the placenta after 8 weeks of 
gestation. P has a physiological eﬀect on uterine quiescence via regulation the intracellular 
calcium level, prostaglandin production and myometrial oxytocin receptor concentration 
(Renzo et al. 2005). Although progesterone treatments seem eﬀective in patients with risk of 
preterm birth, collection more data in large randomised controlled trials are needed for 
conﬁrmation its beneﬁt in the prevention of preterm delivery. 
Ca2+ channel antagonists (have been used increasingly in tocolytic therapy. Those agents that 
inhibit the calcium channels able to block directly the transfer of calcium ions across the cell 
membrane and from the sarcoplasmic reticulum. These actions lead to a decrease in 
intracellular free calcium and inhibition of myosin light-chain kinase–mediated 
phosphorylation resulting in myometrial relaxation (Simhan and Caritis 2007). Nifedipine is 
the most commonly used drug for inhibition of preterm labour and had a similar tocolytic 
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eﬀect compared with β adrenergic receptor agonists, but no placebo-controlled trials have 
adressed the efficacy and safety of nifedipine for this indication. 
 
Figure 1. Sites of action of the commonly used tocolytic agents (Simhan and Caritis 2007). 
It is a pharmacological challenge to find new effective therapeutic strategies, mechanisms or 
combinations to reducing the potentially maternal and foetal adverse effects and improving 
the perinatal outcome. The ideal tocolytic agent should be easy to administer, inexpensive, 
without significant maternal, fetal or neonatal side effects, and effective at postponing preterm 
birth. 
1.3 RhoA and Rho-kinases, general overview 
Rho is small GTP bindig protein, which is one of the major families of Ras superfamily. Rho 
was discovered in 1985 in Aplysia as a Ras homolog protein. Rho-like proteins were 
identified in all eukaryota species (Hall 2012). The Rho family members are molecular 
switches, they able to modulate the signal transduction pathways via interchange of their 
conformational states. The GDP-bound form of Rho is inactive and the active state is exist, 
when bound GTP (Ridley 2001). The Rho family can be subdivided into six families by based 
on the primary amino acid sequence, structural motifs and biological function: the RhoA-
related subfamily such as RhoA, RhoB and RhoC; the Rac1-related subfamily including 
Rac1, Rac2, Rac3 and RhoG; the Cdc42-related subfamily with members of Cdc42, TC10, 
TCL, Chp/Wrch-2 and Wrch-1; the Rnd subfamily such as Rnd1, Rnd2, and RhoE/Rnd3; the 
RhoBTB subfamily; and the recently described Miro subfamily (Wennerberg and Der 2004). 
The RhoA-related proteins exhibit significant amino acid sequence identity (~85%), but they 
have any functional differences. The activation of Rho family members are regulated by 
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several factors and proteins. The ratio of the GDP/GTP form of RhoA is regulated by the 
activity of guanine nucleotide exchange factor (GEF) and the GTP-ase activating ptoteins 
(GAP). GEF promotes the dissociation of GDP and facilitates the GTP binding to RhoA. 
GAPs enhance the GTP hydrolysis rate and increase the GTPase activity of RhoA. 
Furthermore, an other molecules. the guanine nucleotide dissociation inhibitors (GDI) play a 
role in the regulation of GDP/ GTP-bound state of RhoA by inhibiting of the exchange of 
GTP and the hydrolysis of GTP, thereby the RhoA don’t able to bind to the membranes and to 
activate their effectors (Wettschureck and Offermanns 2002) (Figure 2). 
 
Figure 2. Regulation of Rho activity. Guanine nucleotide exchange factor (GEF) proteins catalyze the 
exchange of GDP for GTP on Rho GTPases resulting in their activation. GTPase-activation proteins 
(GAP) and GDP-dissociation inhibitors (GDI) have a negative regulatory role causing the inactivation 
of Rho. PKN Protein kinase N; p140mDia Mammalian homolog of Drosophila diaphanous; citron 
citron-kinase (Wettschureck and Offermanns 2002). 
The small RhoA takes part in several cellular function including cell adhesion, cell motility, 
migration, and cytokinesis. Several effectors of RhoA have been discovered, but the first and 
the best characterized RhoA effector is the Rho-kinase (Loirand et al. 2006). Rho-kinase 
(ROCK) is a serine/threonine protein kinase. Two isoforms of ROCK have been identified, 
ROCK I or ROKβ and ROCK II or ROKα. ROCK-1 and ROCK-2 are highly homologous, the 
identity of amino acid sequence is 65%; the RBD is 58% and the kinase domain is 92% 
(Nakagawa et al. 1996). Human ROCKs genes are located on chromosome 18 (18q11.1) and 
chromosome 2 (2p24), respectively. The sequences of ROCKs involve in a kinase domain at 
the N terminal end, a Rho-binding domain (RBD) in the middle portion and a pleckstrin-
homology (PH) domain with a cysteine-rich domain at the C terminal end (Amano et al. 
2000). The PH domain is a split into two region by insertion of cysteine-rich region. GTP 
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bound Rho able to interact with the RBD domain and activates the phosphotransferase activity 
of Rho-kinase. 
 
Figure 3. Model for the regulation of Rho-kinase. RB: Rho-binding domain; PH: pleckstrin-homology 
domain; AA: arachidonic acid (Amano et al. 2000). 
The activation of Rho-kinases depend on the conformational state of RhoA. However, the 
stimulatory effect of activated RhoA on the activity of ROCKs is limited. Molecules such as 
arachidonic acid or sphingosine phosphorylcholine are able to provoke the activation of 
ROCK independently of RhoA. 
The Rho-kinases expressed in different part of the human body. It has been reported that, 
ROCK II is highly expressed in the brain and slightly in the lung. ROCK I is expressed hardly 
in the brain, skeletal muscles, lung, kidney, pancreas and medium level in the placenta and 
liver (Matsui et al. 1996). 
1.4 The RhoA/Rho-kinase pathway in the smooth muscle 
The contraction or relaxation state of the smooth muscle depends on the interaction between 
actin and myosin. This process is regulated by the activity of myosin light chain kinase 
(MLCK) and myosin phosphatase (MLCP). MLCK is responsible for the phosphorylation of 
the myosin light chain (MLC), thereby MLCK takes part in the initiation of the contraction. 
MLCP able to dephosphorylate the MLC resulting in relaxation.  One of the major 
mechanisms of the smooth muscle contraction is depend on the massive increase in 
intracellular calcium. Calcium ions bind to calmodulin and activate MLCK, which 
phosphorylates the 20 kDa regulatory subunit of the myosin light chain (MLC → pMLC) and 
contributes to activation of contraction (Webb, 2003). In addition, a second pathway has been 
identified (Kimura et al. 1996), which is independent of Ca2+ and includes the GTP binding 
RhoA and ROCKs (Somlyo and Somlyo 2000). The active, GTP-bound RhoA activates their 
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effectors leading to the phosphorylation of regulatory myosin- binding subunit of MLCP 
which results in the inhibition of the phosphatase activity (Taggart et al. 2012). Furthermore, 
the Rho-kinases phosphorylate direct the myosin light chain. These mechanisms promote the 
enhancement of the phosphorylated MLC and induce smooth muscle contraction (Figure 4.)  
 
 
 
 
 
Figure 4. RhoA/Rho-kinase signal pathway in the uterine myocyte (Taggart et al. 2012) 
Pathological activity of RhoA and Rho-kinase in smooth muscle leads to hypertension 
(Uehata et al. 1997) asthma (Chiba et al. 2010), thrombin-stimulated vascular smooth muscle 
migration and endothelial contraction. Therefore, the Rho/Rho-kinase mediated pathway can 
be a possible target for therapeutic interventions in various diseases. 
RhoA/Rho-kinase pathway can be inhibited at several stages: at the receptor by antagonists to 
the activating agonist, by hydrolysis of bound GTP to GDP facilitated by GAPs, by 
complexation of free RhoA with GDI, through deactivation of Rho-kinases by inhibitors. 
Simvastatin, a HMG-CoA reductase inhibitor ables to block the synthesis of geranylgeranyl 
pyrophosphate, which is needed to posttranslational lipidation, membrane localization, and 
function of RhoA (Park et al. 2002). 
Y-27632 as a specific inhibitor of ROCKs able to block the agonist-induced contraction of 
vascular and bronchial smooth muscles by inhibiting the Ca senzitization and blocks the Rho-
kinase activity by competing with ATP for binding to the kinase (Ishizaki et al. 2000). The 
other non isoform selective Rho-kinase inhibitor is the fasudil, which is the only ROCK 
inhibitor that is applied in clinical practice and has been used in Japan to treat cerebral 
vasospasm (Asano et al. 1989). Fasudil inhibits the Rho-kinase mediated myosin light chain 
phosphorylation and suppresses the myosin phosphatase activity (Fukata et al. 2001). The 
development of fasudil began the functional research of quinoline or isoquinoline derivatives 
by chemical screening to measure their vasodilatory activity in normal and spastic arteries. 
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Several preclinical data suggest the benefits of ROCK inhibition in cardiovascular diseases, 
therefore many biotechnology and pharmaceutical companies are synthetized and developed 
ROCK inhibitors. RKI-1447 has a similar inhibitory activity to Y-27632 and fasudil. It 
inhibits ROCKI and ROCKII dose-dependence with IC50 values of 14.5 nM and 6.2 nM (Patel 
et al. 2012).   
There are few and variant data about the expression of RhoA, ROCK I and ROCK II in 
pregnant uterus (Moran et al. 2002, Gao et al. 2009) and cervix, as well as the effects of RhoA 
and ROCK inhibitors at different stages of pregnancy.  
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2. Aims 
 
- The aim of our study was to investigate the ontogeny of the mRNA and protein 
expression of RhoA, ROCK I, and its isoform, ROCK II in pregnant rat uteri and 
cervix by using real-time PCR and Western blot analysis. 
 
- The other purpose was to evaluate the effects/roles of the RhoA and Rho-kinases (Y-) 
on uterine contractility and cervical resistance in isolated organ bath experiments in 
vitro by using RhoA inhibitor simvasvatin and ROCK inhibitors Y-27632, fasudil and 
RKI 1447. 
 
 
- Our further aim was to analyse the effects/efficiancy of newly synthetized isoquinoline 
derivatives on the pregnant and non-pregnant uterine contractions in vitro, and to test 
their actions on ROCK activity as compared with well-known reference compounds.  
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3.  Materials and Methods 
3.1. Housing and handling of the animals 
All experiments involving animal subjects were carried out with the approval of the National 
Scientific Ethical Committee on Animal Experimentation (permission number: IV/198/2013). 
The animals were treated in accordance with the European Communities Council Directives 
(2010/63/EU) and the Hungarian Act for the Protection of Animals in Research (Article 32 of 
Act XXVIII). Sprague–Dawley rats (Charles-River Laboratories, Hungary) were kept at 22±3 
°C; the relative humidity was 30–70% and the light/dark cycle was 12/12 h. The animals were 
maintained on a standard rodent pellet diet (Charles-River Laboratories, Hungary) with tap 
water available ad libitum. They were euthanized by CO2 inhalation. 
3.2. Mating of the animals 
The mature female (180-200 g) and male (240-260 g) rats were mated in a special mating 
cage. A movable metal door separated the spaces for the female and male animals. A timer 
controlled the function of the engine that moved the separating door. Because rats are usually 
active at night, the door was opened before dawn. Within 4-5 h after the possibility of mating, 
vaginal smears were taken from the female rats and a sperm search was performed under a 
microscope at a magnification of 1200. If the search proved positive or a vaginal sperm plug 
was visible, the female rats were separated and were regarded as first-day pregnant animals. 
3.3. Tissue isolation  
The animals were euthanized in a CO2 chamber. Uterus and cervix tissues were rapidly 
removed from 5- , 15-, 18-, 20- and 22-day –pregnant animals, non-pregnant ones, as well as 
those in labour and post-partum (1, 3 and 5 days after labour). During labour the tissues were 
dissected always after delivery of the 3rd pup). The cervix side and the ovary side uterine rings 
were not collected. The remaining tissue samples were washed in ice-cold saline (0.9% NaCl) 
and then transferred to a solution containing recombinant ribonuclease inhibitor (RNAlater, 
Life Technologies, Hungary). The samples were frozen in liquid nitrogen and stored at –70 °C 
until total RNA and protein extraction. We also investigated the non-pregnant, day 22 
pregnant and parturient endometrium and myometrium separately. The endometrium was 
removed and collected by gentle and careful scraping of the inner surface of the uterine horns 
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with the blunt edge of a scalpel. The endometrial samples were also stored at 4°C overnight in 
RNAlater solution (Life Technologies, Budapest, Hungary), the supernatant was then 
removed, and the samples were stored at -70 °C until the beginning of the investigation.  
3.4. Real time quantitative polymerase change reaction study 
The uterine and cervical tissues were frozen in liquid nitrogen, then these were mechanically 
homogenized. Total RNA was isolated from samples using TRI Reagent (Molecular Research 
Centre, Inc., Cincinnati, OH, USA). The quantities of RNA were assessed via the ratio of the 
absorbance at 260 and 280 nm; all samples exhibited ratios in the 1.6-2.0 range. The 
following primers were used for amplification of the PCR products: Rn04219609_m1 for 
RhoA, Rn00579490_m1 for Roc1, Rn00564633_m1 for Roc2 and Rn00667869_m1 for ß-
actin as an endogenous control (Life Technologies, Hungary). PCR products were amplified 
with the SensiFAST Probe HiROX One-Step Kit (Bioline, Csertex Ltd., Hungary) and the 
ABI StepOne Real-Time cycler. The following conditions were used for amplification: 45°C 
for 10 min, 95°C for 2 min and 40 cycles of 95°C for 5 sec, 60°C for 20 sec. The fluorescence 
intensities of the probes were plotted against PCR cycle numbers. The amplification cycle 
displaying the first significant increase in the fluorescence signal was defined as the threshold 
cycle (CT). 
3.5.  Western blot analysis 
Samples were powdered with a Sartorius MikroDismembrator U (Sartorius, Göttingen, 
Germany) and homogenized in a RIPA Lysis Buffer combined with PMSF solution, sodium 
orthovanadate solution and protease inhibitor cocktail solution (Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA, USA). 50 µg of protein per well was subjected to electrophoresis on 
4−12% NuPAGEBis-Tris Gel in XCellSureLock Mini-Cell Units (Life Technologies, 
Budapest, Hungary). Proteins were transferred from gels to nitrocellulose membranes using 
the iBlot Gel Transfer System (Life Technologies, Budapest, Hungary). Antibody binding 
was detected with the WesternBreeze Chromogenic Western Blot Immundetection Kit (Life 
Technologies, Budapest, Hungary). The incubation with RhoA, Roc1, Roc2 and β-actin 
polyclonal antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:200) were made 
on a shaker in the blocking buffer. The optical density of each immunoreactive band was 
determined with Kodak 1D Images analysis software (Carestream Health, Inc., Rochester, 
NY, USA). Optical densities were calculated as arbitrary units after local area background 
subtraction. 
15 
 
3.6.  Rho-kinase activity assay 
The Rho-kinase activity was measured by an immunoassay recommending by the 
manufacturer (Merck Ltd., Hungary). All compounds were added in 200 µM final 
concentration to the assay. Briefly, 50 μl samples containing 10 mUnit of active ROCK II 
with and without inhibitors were added into a 96-well plate, that was pre-coated with 
recombinant myosin phosphatase target subunit 1 (MYPT1). After 30 min incubation at 30 
°C, the plate was washed three times with 1X Wash buffer (combination of 20X TBS, 20% 
Tween® and distilled water), then incubated with 100 μl/well of anti-phospho- MYPT1 
antibody for 1 h at room temperature. After washing, 100 μl/well of HRP-conjugated 
secondary antibody was added and incubated for 1 h at room temperature. After the addition 
of 100 μl/well of chromogenic substrate reagent, the reaction was terminated by adding 
100 μl/well of the stop solution. The absorbance was measured on a 96-well plate reader 
(SpectroStarNano, BMG Labtech, Germany) at 450 nm. The absorbance signal reflects the 
relative amount of ROCK activity. Each data point was performed in triplicate and the assay 
was repeated twice. 
3.7. In vitro organ bath study 
3.7.1. Uterus preparation 
5-mm-long uterine rings were removed from non-pregnant rats in the oestrus phase (180-200 
g) and from rats on pregnancy day 22, during labour and on the first day after the parturition 
and then mounted vertically in an organ bath. The bath contain 10 ml of de Jong solution 
(137mM NaCl, 3mM KCl, 1mM CaCl2, 1mM MgCl2, 12mM NaHCO3, 4mM NaH2PO4, 
6mM glucose, ph 7.4) and was maintained at 37 ºC, and carbogen (95% O2 + 5% CO2) was 
bubbled through it. After being mounted, the rings were equilibrated for about 1 h with a 
change of solution every 15 min. The initial tension was set at 1.5 g. The tension of the 
myometrial rings was measured with a gauge transducer (SG-02) and recorded with a SPEL 
Advanced ISOSYS Data Acquisition System (MDE Ltd., Budapest, Hungary). 
3.7.2. Oxytocin-induced contractions study 
3.7.2.1. Contraction with presence simvastatin, fasudil, Y-27632 and RKI 1447 
After the incubation period, uterine contractions were elicited with 10-8 M oxytocin. To 
measure the extent of fatigue, the oxytocin-induced contractions were recorded for 30 min 
without inhibitors in control experiments. Cumulative dose-response curves were constructed 
in the concentration range of 10-10 -10-5 M with the presence of Rho-kinase inhibitors RKI 
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1447 (Avidin Kft., Szeged, Hungary), fasudil, Y-27632 or RhoA inhibitor simvastatin 
(Sigma-Aldrich, Budapest, Hungary). The effects of each concentration of the inhibitors were 
recorded for 300 s. The areas under the curves (AUC) were evaluated and analysed, then 
concentration-response curves were fitted. The maximum inhibition (Imax) and the 
concentration to elicit 50% of the maximum inhibitions of uterine contraction (IC50) were 
calculated with the Prism 5.0 (Graphpad Software, Inc., San Diego, CA, USA) computer 
programs. All the experiments were carried out on at least 6 animals, and the values are given 
as means ± SEM. For statistical evaluations, data were analysed by one-way ANOVA 
Tukey’s test. 
3.7.2.2. Contraction with presence of newly synthetized isoquinolines 
25 isoquinoline derivatives (13 water-soluble and 12 non-water-soluble) were selected from 
the Departmental Compound Library of the Institute of Pharmaceutical Chemistry, University 
of Szeged, including some N,N-disubstituted 6,7-dialkoxy-phenylethylamines. The uterus 
preparation was carried out by the above described method. 
Uteri were removed as previously described from non-pregnant, day 20 of pregnancy and 
during parturiton. We measured the effects of the newly synthetized isoquinoline derivatives, 
fasudil and Y-27632 on the uterine contractions precontracted with 10-8 M oxytocin. 
Cumulative dose-response curves were constructed in the concentration range of 10-10 -10-5M. 
The effects of each concentration of the inhibitors were recorded for 300 s. The maximum 
inhibitory effects (Emax) of isoquinoline derivatives, fasudil and Y-27632 were calculated 
from the changes of the AUC values, while the half maximal inhibitory concentration (IC50) 
values were determined as the concentration required to reach the halfway point between the 
top and bottom plateaus of the inhibitory curve. All these values were calculated with the 
Prism 5.0 (Graphpad Software, Inc., San Diego, CA, USA) computer program. For statistical 
evaluations, data were analyzed with unpaired t-test or ANOVA, Tukey’s Multiple 
Comparison Test. 
           FF 852                               FF 218 
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3.7.3. Cervical resistance study 
The whole cervical tissues were removed freshly from non-pregnant (oestrus phase), 20- and 
22-day pregnant rats. The tissues were cut into two rings and mounted with their longitudinal 
axis vertically by hooks in an organ bath containing 10 ml de Jongh buffer (137mM NaCl, 
3mM KCl, 1mM CaCl2, 1mM MgCl2, 12mM NaHCO3, 4mM NaH2PO4, 6mM glucose, ph 
7.4). The organ bath was maintained under standard condition (37ºC with carbogen - 95% O2 
+ 5% CO2–bubbling). The rings were equilibrated for about 1 h with a change of buffer 
solution every 15 min. The initial tension was set at 1.0 g. RhoA inhibitor (simvastatin) or 
Rho-kinase inhibitors (Y-27632, fasudil) (Sigma-Aldrich, Budapest, Hungary) were added to 
the organ bath in a concentration of 10-6M and the cervices were incubated for 5 min. Then 
the rings were stretched in incremental steps and allowed to relax for 5 min. After every 5 
min, the next initial tension was set, in 1.0 g steps between 1.0 g and 12.0 g. The tension was 
increased manually via the control screw of a gauge transducer and recorded by ISOSYS 
software (MDE Heidelberg, Waldorf, Germany). Evaluation of the cervical resistance was 
carried out such that the initial tension of the cervix was represented versus the stretch after 5 
min. Straight lines were fitted by linear regression and the slopes of the lines were used to 
express the degree of resistance. A steeper slope reflected a higher resistance (Gáspár et al., 
2005; Gál et al, 2009). 
All the experiments were carried out on at least 6 animals, and the values are given as means 
± SEM. For statistical evaluations, data were analysed by one-way ANOVA Dunett test. 
 
 
 
 
 
 
 
 
18 
 
4. Results 
4.1. Expression of RhoA, ROCK I and ROCK II in the rat uterus 
4.1.1. Alteration of RhoA in the uterus 
The mRNA and protein expression of RhoA and Rho-kinases were investigated in the non-
pregnant, pregnant and postpartum rat uterus. The mRNA level of RhoA decreased in the 5th 
day of pregnancy and slightly increased till day 18, while a decrease was detected till day 22, 
however, these alterations were not significant. During labour a sharp increase was found in 
mRNA expression compared to day 22, then reduced on postpartum day 1 and remained 
unchanged on postpartum days 3, 5 and 7 (Fig. 5A). The protein level of RhoA did not 
change significantly until day 22 of pregnancy, while a marked increase was found during 
labour. Interestingly, the elevated RhoA protein expression were unchanged on postpartum 
day 1, but it was significantly reduced from postpartum day 3 (Fig. 5B).  
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Figure 5. Changes in mRNA (A) and protein level (B) of RhoA in non-pregnant rat uterus (np) during 
pregnancy, during parturition (dp) and on postpartum days (pp1, 3, 5 and 7). The significances are 
given as compared with data on the previous day. Each bar indicates the mean ± SEM (standard error); 
n=6. ANOVA, Tukey’s test.ns:non-significant; * p < 0.05; ** p < 0.01. 
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The mRNA and protein expression of RhoA were also investigated in endometrial and 
myometrial tissues (Fig. 6) separately. The mRNA expressions of RhoA did not change 
significantly in the endometrial samples (Fig. 6A), but decreased in the myometrium on 22th 
of pregnancy and during parturition (Fig.6B). Interestingly, the protein level of RhoA 
markedly increased in the endometrial samples during delivery (pregnancy day 22 and during 
parturition) (Fig. 6C) and remained unchanged in myometrium (Fig. 6D). 
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Figure 6. Changes the RhoA mRNA and protein expression in endometrium and myometrium in non-
pregnant rat (np), day 22 of pregnancy (22) and during parturition (dp) in endometrium (C, E) and 
myometrium (D, F). The significances are given as compared with data of non-pregnant state. Each 
bar denotes mean ± SEM (standard error); n=5.ANOVA, Tukey’s test. ns: non-significant; * p < 0.05; 
*** p < 0.001. 
 
4.1.2. Alteration of ROCK I and ROCK II in the uterus 
We found that the mRNA level of ROCK I was high in non-pregnant uterus that was 
decreased in pregnancy day 5 and remained low till parturition. However a 5-fold increase 
was detected during labour and that was reduced moderately on postpartum day 1 and 
remained unchanged on the postpartum period (Fig. 7A). The protein expression of ROCK I 
A B 
C D 
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followed a similar pattern till pregnancy day 18 to that of mRNA expression. On pregnancy 
day 18 the protein expression was elevated, and a further increase was detected during labour. 
The further alterations of ROCK I protein expression after labour were similar to those of the 
mRNA expression (Fig. 7B).  
np 5
 
15
 
18
 
20
 
22
 
dp pp
1
pp
3
pp
5
pp
7
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
***
ns
ns ns ns
***
***
ns
ns
ns
R
Q
 (
re
la
ti
v
e
 q
u
an
ti
ty
)
 o
f 
R
O
C
K
 I 
m
R
N
A
 
    
np 5 15 18 20 22 dp pp
1
pp
3
pp
5
pp
7
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
*** ns
***
ns
ns
***
***
ns
*
nsO
pt
ic
al
 d
en
si
ty
 o
f R
O
C
K
 I
 
Figure 7. The mRNA (A) and protein expression (B) of ROCK I in non-pregnant rat uterus (np) 
during pregnancy, during parturition (dp) and on postpartum days (pp1, 3, 5 and 7). The significances 
are given as compared with data on the previous day. ns:non-significant; * p < 0.05; ** p < 0.01; *** 
p < 0.001. Each bar indicates the mean ± SEM (standard error); n=6. ANOVA, Tukey’s test. 
 
In case of ROCK II, a low mRNA level was observed from non-pregnant uteri to day 22 of 
pregnancy and then a sharp increase was found during parturition (Fig. 8). On the first day 
after delivery, the ROCK II mRNA expression significantly decreased then remained 
unchanged till postpartum day 7 (Fig. 8A). Interestingly, the protein expression of ROCK II 
was high in the non-pregnant uteri, that was significantly reduced on pregnancy days 5 and 15 
(Fig.8B). On day 18 the protein level was increased, then a reduced protein level was 
measured till delivery, while during parturition the protein expression of ROCK II 
significantly enhanced. On postpartum days (1, 3, 5, 7) low protein levels were detected.  
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Figure 8 The mRNA (A) and protein level (B and C) of ROCK II in non-pregnant rat uterus (np) 
during pregnancy, during parturition (dp) and on postpartum days (pp1, 3, 5 and 7). The significances 
are given as compared with data on the previous day.ns:non-significant; * p < 0.05; ** p < 0.01; *** 
p < 0.001.Each bar indicates mean ± SEM (standard error); n=6. ANOVA, Tukey’s test. 
 
 
 
 
 
 
4.2. Effects of RhoA inhibitor simvastatin and Rho-kinase inhibitors y-27632, fasudil 
and RKI1447 in vitro 
Simvastatin (10-10-10-5 M) inhibited the oxytocin-induced uterine contractions in a dose-
dependent manner. The weakest relaxing activity was found on postpartum day 1, while the 
B 
A 
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strongest relaxing effect was measured on day 22 of pregnancy. Simvastatin elicited a similar 
relaxing effect on non-pregnant uterus and during parturition, but its activity was lower as 
compared with day 22 of pregnant uterus (Fig. 9).  
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Figure 9 Inhibitory effects of simvastatin on oxytocin-stimulated contraction in myometria in vitro in 
non-pregnant (np) rats and day 22 of pregnancy, during parturition (dp) and on the first day of the 
post-partum period (pp1).  
The IC50 value of simvastatin was the lowest on pregnancy day 22 and the highest on 
postpartum day 1, while these values in non-pregnant uterus and during parturition were 
similar (Table 1). 
 np day 22 dp pp1 
IC 50 ± SEM 4.6e-008 ± 
9.3e-007 
7.0e-009 ± 
2.4e-009ns 
7.6e-008 ± 
1.8e-008ns 
2.8e-006 ± 
1.4e-007* 
Inhibition% 
± SEM 
58.3 ± 4.7 90.1 ± 1.1*** 71.7 ± 2.2*** 19.7 ± 5.5*** 
Table 1 The maximum inhibition and the IC50 values of simvastatin. The significances are given as 
compared with data on the previous day.np: non-pregnant, dp: during parturition, pp: postpartum; ns: 
non-significant; * p < 0.05; *** p < 0.001. Each bar denotes mean ± SEM (standard error). ANOVA, 
Tukey’s test. 
Each non-selective Rho-kinase inhibitor (fasudil, Y-27632 and RKI 1447) inhibited the 
oxytocin induced contractions dose-dependently. Fasudil had the strongest inhibitory effect on 
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non-pregnant uteri, while it elicited similar relaxation on day 22, during parturition and 
postpartum day 1 (Fig. 6).  
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Figure 6 The inhibitory effect of non-selective ROCK inhibitor fasudil on the non-pregnant rat uteri 
(np), on pregnancy day 22, during parturition (dp) and on the first day of the postpartum period (pp1). 
 
The IC50 values of fasudil were very similar on all investigated days (Table 2). 
Table 2 The maximum inhibition and the IC50 values of fasudil. The significances are given as 
compared with data on the previous day.np: non-pregnant; dp: during parturition; pp:postpartum. ns: 
non-significant; * p < 0.05; ** p < 0.01. Each bar denotes mean ± SEM (standard error). ANOVA, 
Tukey’s test. 
 
The compounds Y-27632 (Fig. 7) and RKI 1447 (Fig. 8) showed a very similar action: they 
had a strong relaxing effect on non-pregnant uteri and during parturition, while their action 
was moderated on day 22 and postpartum day 1.  
 np day 22 dp pp1 
IC 50 ± SEM 
7.7e-008± 
1.6e-008 
2.0e-007± 
4.0e-008
ns 
1.7e-007± 
2.4e-008
ns 
1.0e-006± 
1.4e-007
ns 
Inhibition% ± 
SEM 
80.7 ± 2.3 58.8 ± 3.4** 57.2 ± 4.9ns 71.9 ± 5.2* 
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Figure 7 The inhibitory effect of non-selective ROCK inhibitor Y-27632 on the non-pregnant rat uteri 
(np), on pregnancy day 22, during parturition (dp) and on the first day of the postpartum period (pp1). 
 
Y-27632 had the highest IC50 values on postpartum day 1. The lowest values of Y-27632 
(Table 3) were measured in non-pregnant uteri. 
 
 
 np day 22 dp pp1 
IC 50 ± SEM 2.7e-007 ± 
3.6e-007 
4.9e-006 ± 
4.3e-007
ns 
1.3e-006 ± 
3.7e-007
ns 
5.3e-006 ± 
2.0e-007
ns
 
Inhibition% ± 
SEM 82.3 ± 3.5 51.9 ± 8.3
** 78.8 ± 2.5** 61.7 ± 8.6ns 
Table 3 The maximum inhibition and the IC50 values of Y-27632. The significances are given as 
compared with data on the previous day.np: non-pregnant; dp: during parturition; pp: postpartum.ns: 
non-significant; ** p < 0.01. Each bar denotes mean ± SEM (standard error). ANOVA, Tukey’s test. 
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Figure 8 The inhibitory effect of non-selective ROCK inhibitor RKI-1441 on the non-pregnant rat 
uteri (np), on pregnancy day 22, during parturition (dp) and on the first day of the postpartum period 
(pp1). 
 
The highest IC50 values of RKI 1441 were found on postpartum day 1, while lowest values 
were measured on day 22 and during parturition (Table 4). 
 
 np day 22 dp pp1 
IC 50 ± SEM 
7.6e-008 ± 
2.1e-008 
2.5e-008 ± 
3.0e-009
ns 
2.1 e-008 ± 
2.4e-008
ns 
1.7e-007± 
3.8e-007
**
 
Inhibition% ± 
SEM 
76.9 ± 2.8 51.0 ± 2.8*** 70.8 ± 2.7** 40.7 ± 3.9*** 
Table 4 The maximum inhibition and the IC50 values of RKI-1447. The significances are given as 
compared with data on the previous day.np: non-pregnant; dp: during parturition; pp: postpartum.ns: 
non-significant; ** p < 0.01; *** p < 0.001. Each bar denotes mean ± SEM (standard error). ANOVA, 
Tukey’s test. 
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4.3. Effects of newly synthetized isoquinoline derivatives for the uterine contraction 
in vitro 
We have synthesized 13 water-soluble and 12 non-water-soluble isoquinoline molecules. 
Their efficacies were investigated on the non-pregnant rat uterine contractions. The IC50 
values of 11 from among the 25 derivatives were significantly lower on the oxytocin-induced 
contraction compared with Y-27632 and fasudil (Table 5, 6), although their maximal 
inhibitory effects were weaker than those of Y-27632 and fasudil. Interestingly, the IC50 
values of papaverine and drotaverine were less pronounced than those of Y-27632 (Table 5) 
and fasudil, but they showed similar maximal effects to the control molecules. 
 IC50 ± SEM Emax ± SEM 
Y-27632 5.05e-007 ± 1.19e-007 82.31 ± 3.49 
fasudil (/) 7.81e-007 ± 2.32e-007 ns 87.37 ± 1.51 ns 
192 1.89e-008 ± 4.64e-009 **/** 49.57 ±1.46 ***/ *** 
214 9.81e-008 ±2.91e-008 */* 51.72 ± 1.98 ***/ *** 
218 4.18e-008 ± 1.18e-008 **/** 46.3 ± 3.42 ***/ *** 
716 9.02e-008 ± 2.13e-008 **/* 45.57 ± 3.06 ***/ *** 
724 6.1e-007 ± 2.39e-007 ns /ns 58.76 ± 1.94 ***/ *** 
890 3.71e-008 ± 1.52e-008 **/* 47.95 ± 1.76 ***/ *** 
1030 2.42e-008 ± 4.76e-009 **/* 47.33 ± 2.07 ***/ *** 
1370 8.24e-009 ± 1.38e-009 **/** 43.67 ± 1.06 ***/ *** 
1374 7.88 e-007 ± 1.96e-007 ns/ns 57.25 ± 4.52 ***/ *** 
1386 3.22e-008 ± 1.37e-008 **/** 54.53 ± 2.89 ***/ *** 
1525 1.33e-008 ± 2.09e-009 **/** 50.38 ± 1.63 ***/ *** 
1634 1.17e-006 ± 1.93e-007 */ns 82.51 ± 3.44 ns/ ns 
3641 1.12e-006 ± 8.23e-007 ns/ns 59.78 ± 7.04 ***/ *** 
papaverine 4.2e-007 ± 1.07e-007 ns/ns 98.52 ± 0.78 */ ns 
drotaverine 1.94e-006 ± 4.51e-007 **/* 88.79 ± 8.83 ns/ ns 
Table 5 
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Table 5 and 6. Half maximal inhibitory concentration (IC50) values and the maximal inhibitory effects 
(Emax) of the water and non-water soluble isoquinoline derivatives. The IC50 was determined as the 
concentration required to reach the halfway point between the top and bottom plateaus of the 
inhibitory curve. Significances are compared to the values of Y-27632 or fasudil (/). Statistical 
analysis was carried outwith ANOVA, Tukey’s Multiple Comparison Test. ns: non-significant; * 
p < 0.05; **p < 0.01 *** p < 0.001 
 
According to the significant IC50 values, we measured the effects of isoquinoline molecules 
on ROCK II activity. We found 2 isoquinolines out of 11 compounds (218 and 852) that have 
ROCK II inhibiting activity similar to that of Y-27632 (Figure 9). 
 IC50 ± SEM Emax ± SEM 
y 27632 5.05e-007 ± 1.19e-007 82.31 ± 3.49 
fasudil 7.81e-007 ± 2.32e-007 ns 87.37 ± 1.51ns/ns 
28 1.91e-007 ± 1.0e-007 ns/ns 52.83 ± 2.15 ***/*** 
787 7.23e-007 ± 1.24e-007 ns/ns 76.64 ± 5.72 ns/ns 
835 8.45e-008 ± 2.04e-008 **/ ** 54.46 ± 5.78 ***/ *** 
842 2.63e-007 ± 1.18e-007 ns/ns 66.41 ± 6.48 ns/ ** 
852 1.58e-007 ± 3.25e-008 */ * 52.52 ± 1.89 ***/ *** 
854 2.78e-007 ± 1.29e-007 ns/ns 53.31 ± 2.22 ***/ *** 
858 1.19e-006 ± 1.37e-007 **/ns 83.55 ± 2.02 ns/ns 
1390 4.95e-007 ± 1.84e-007 ns/ns 54.53 ± 1.78 ***/ *** 
1521 5.22e-007 ± 3.37e-007 ns/ns 55.1 ± 3.09 ***/ *** 
1649 2.58e-007 ± 1.09e-007 ns/ns 53.2 ± 1.71 ***/ *** 
2263 1.25e-006 ± 2.06e-007 */ns 72.23 ± 2.54 ns/ ns 
2295 1.08e-006 ± 5.4e-007 ns/ns 84.71 ± 7.51 ns/ns 
Table 6 
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Figure 9. The inhibitory effects of the isoquinoline derivatives for ROCK II activity. The 
significances are given as compared with Y-27632. Each bar denotes mean ± SEM (standard error). 
Statistical analysis was carried out with ANOVA, Tukey’s Multiple Comparison Test. ns: non-
significant; * p < 0.05; **p < 0.01 *** p < 0.001 as compared with the inhibitory effect of Y-27632.  
 
We measured the relaxing effects of two isoquinoline derivatives, 218 and 852, on day 20 of 
the pregnant rat uterus (when the expression of ROCKs were low). We found that the 
inhibitory IC50 values of 218 (Figure 10A) and 852 (Figure 10B) were markedly lower than 
those of fasudil.  
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Figure 10. The inhibitory effects of 218 (A) and 852 (B) isoquinoline derivatives on the 20th-day 
pregnant rat uterus. Statistical analysis was carried out with ANOVA, t-test 
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Moreover, 218 and 852 relaxed the rat uteri during parturition (when the expressions of 
ROCKs were high) with greater potency as compared with fasudil (Figure 11A and B).  
-11 -10 -9 -8 -7 -6 -5
0
10
20
30
40
50
60
70
80
90
100 218
fasudil
during parturition
C
o
n
tr
a
c
ti
o
n
 (
%
)

 S
E
M
         
-11 -10 -9 -8 -7 -6 -5
0
10
20
30
40
50
60
70
80
90
100
fasudil
852
during parturition
C
o
n
tr
a
c
ti
o
n
 (
%
)

 S
E
M
 
Figure 11. The inhibitory effects of 218 (A) and 852 (B) isoquinoline derivatives during 
parturition in rat uterus. Statistical analysis was carried out with ANOVA, t-test. 
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4.4. Expression of RhoA, ROCK I and ROCK II in rat cervix 
4.4.1. The mRNA and protein expression of RhoA in cervix 
The mRNA levels of RhoA did not change till postpartum day 1. However, an increased level 
was detected on postpartum day 3 as compared with the non-pregnant cervix and they were 
high on postpartum day 5 (Figure 12A). The protein levels of RhoA were unchanged till 
pregnancy day 18. On pregnancy day 20 and during parturition, a significant decrease was 
found as compared with the non-pregnant level. In the postpartum period, the protein 
expression of RhoA slighly increased compared with the parturient cervix (Figure 12B). 
 
 
Figure 12. The mRNA (A) and protein expression (B) of RhoA in non-pregnant rat cervix (np), on 
different days of pregnancy, during parturition (dp) and on postpartum days (pp1, pp3, pp5). The level 
of significance is given in two ways. Asterisks represent comparisons to data from non-pregnant 
cervix. ns: non-significant; *: p<0.05; **: p< 0.01; ***: p< 0.001. Hashtags represent comparisons to 
the previous investigated days. #: p<0.05; non-significant changes are not indicated. Each bar denotes 
mean ± S.E.M. (standard error); n = 5. ANOVA, Tukey’s test. 
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4.4.2. The mRNA and protein expression of ROCK I and ROCK II in the cervix 
No change was found in mRNA expression of ROCK I till pregnancy day 20. On pregnancy 
day 22, a sharp increase was measured that was decreased during labour compared with day 
22. Interestingly, on postpartum day 1, the mRNA level was raised again and remained high 
till post-partum day 5 (Fig. 13A). The protein level of ROCK I reduced on pregnancy day 15 
as compared with day 5, while a further decrease was measured on day 18 compared with the 
non-pregnant cervix. A marked increase was detected on pregnancy day 22 compared with 
day 20 that was markedly decreased in parturient cervical tissue. On postpartum day 1 the 
protein level raised as compared with the level during parturition. No further change was 
detected till postpartum day 5 (Fig. 13B). 
 
 
Figure 13. The mRNA (A) and protein expression (B) of ROCK I in non-pregnant rat cervix (np), on 
different days of pregnancy, during parturition (dp) and on postpartum days (pp1, pp3, pp5). The level 
of significance is given in two ways. Asterisks represent comparisons to data from non-pregnant 
cervix. ns: non-significant; *: p<0.05; **: p< 0.01; ***: p< 0.001. Hashtags represent comparisons to 
the previous investigated days. #: p<0.05; ##: p< 0.01; ###: p< 0.001; non-significant changes are not 
indicated. Each bar denotes mean ± S.E.M. (standard error); n = 5. ANOVA, Tukey’s test. 
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The mRNA level of ROCK II did not change significantly from non-pregnant cervix until 
pregnancy day 22, then a sharp decrease was detected during parturition. On postpartum day 
1, thecexpression was markedly increased to the level of non-pregnant and 22-day pregnant 
cervices (Fig. 14A). The alteration of the protein expression of ROCK II followed the same 
pattern of mRNA alterations (Fig. 14B). 
 
   
Figure 14. The mRNA expression (A) and protein expression (B) of ROCK II in non-pregnant rat 
cervix (np), on different days of pregnancy, during parturition (dp) and on postpartum days (pp1, pp3, 
pp5). The level of significance is given in two ways. Asterisks represent comparisons to data from 
non-pregnant cervix. ns: non-significant; **: p< 0.01. Hashtags represent comparisons to the previous 
investigated days. #: p<0.05; ##: p < 0.01; ###: p< 0.001; non-significant changes are not indicated. 
Each bar denotes mean ± S.E.M. (standard error); n = 5. ANOVA, Tukey’s test. 
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4.5. Effects of RhoA inhibitor simvastatin and Rho-kinase inhibitors Y-27632 
and fasudil 
The cervical resistances were continuously decreased towards the end of the gestational 
period. Neither the RhoA inhibitor simvastatin nor ROCK inhibitors (Y-27632 and fasudil) 
significantly altered the resistance of non-pregnant cervices at a concentration of 10-6M. 
However, simvastatin enhanced the cervical resistance in days 20 and 22 of pregnancy 
compared with the non-treated values (Fig.15).  
 
 
 
 
 
Figure 15 Effects of simvastatin on cervical resistance in the non-pregnant, 20- and 22-day pregnant 
cervices. Evaluation of the cervical resistance was carried out such that the initial tension of the cervix 
was represented versus the stretch after 5 min. Straight lines were fitted by linear regression and the 
slopes of the lines were used to express the degree of resistance. The significances are given as 
compared with non-treated (control data). ns: non-significant; *p< 0.05;***: p < 0.001. Each bar 
denotes mean ±S.E.M. (standard error). ANOVA, Tukey’s test. 
 
The Rho-kinase inhibitorY-27632 decreased the resistance of the 20-day pregnant cervix, but 
did not alter the non-pregnant and 22-day pregnant cervical resistances as compared with the 
non-treated samples (Fig. 16).  
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Figure 16. Effects of Y-27632 on the resistances of the non-pregnant, 20- and 22-day pregnant 
cervices. Evaluation of the cervical resistance was carried out such that the initial tension of the cervix 
was represented versus the stretch after 5 min. Straight lines were fitted by linear regression and the 
slopes of the lines were used to express the degree of resistance. The significances are given as 
compared with non-treated (control) data ns: non-significant; *p < 0.05. Each bar denotes mean 
±S.E.M. (standard error). ANOVA, Tukey’s test. 
 
Fasudil did not alter the non-pregnant resistance, but reduced significantly the cervical 
resistances in days 20 and 22 of pregnancy (Fig. 17). 
 
 
 
 
 
 
 
Figure 17. Effects of fasudil on the resistances of the non-pregnant, 20- and 22-day pregnant cervices. 
Evaluation of the cervical resistance was carried out such that the initial tension of the cervix was 
represented versus the stretch after 5 min. Straight lines were fitted by linear regression and the slopes 
of the lines were used to express the degree of resistance. The significances are given as compared 
with non-treated (control) data. ns: non-significant; *p< 0.05; **p< 0.01. Each bar denotes mean 
±S.E.M. (standard error). ANOVA, Tukey’s test. 
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5. Discussion 
 
The normal conformational and physiological changes of the uterus and cervix are necessary 
to be maintained the quiescent state throughout pregnancy as well as the initiation of powerful 
rhythmic contractions at term. The precise trigger mechanism of pregnant uterine contractions 
and cervix dilatation are yet unknown. An understanding of these processes, at cellular and 
molecular levels, is essential to identify new possible drug targets to develop potent and 
efficacous tocolytic agents.  
Several studies have investigated the contribution of the monomer GTP-binding RhoA and 
the Rho-kinases in cardiovascular diseases (Loirand et al., 2006), in the invasion of cancer 
cells and progression (Kamai et al., 2004; Lin et al., 2007; Yoshioka et al., 1999), and in 
uterine contraction. There are little and inconsistent reports outlining the role of RhoA and 
Rho- kinases in uterine contractility (Niiro et al., 1997; Tahara et al., 2002; Taggart et 
al.,2012) and no information about their role in regulation of cervix maturation or dilatation 
during pregnancy.  
Therefore, we examined the expressions of RhoA and ROCKs and we have found that the 
mRNA level of RhoA and ROCKs decreased in the uterus on day 5 of pregnancy; however, 
the protein expression of RhoA was unchanged on this day as compared with the non-
pregnant level. It is well known that the implantation period in rats is between pregnancy days 
4-7 (Bullock and Bunton, 2000). Fanchin et al. (2001) determined that the human uterine 
contraction is decreased at the time of blastocyst transfers. Furthermore, Shiokawa et al. 
(2000 and 2002) found that the human decidual cells express RhoA and the migration of 
cytotrophoblast cells has been regulated by RhoA/ROCK signalling pathway. Furthermore, 
Rho GTPases contribute to the regulation of the invasion of the embryo into the endometrial 
stroma (Grewal et al., 2008) via modulating actin, myosin, and microtubule dynamics 
(Etienne-Manneville and Hall 2002). The decreased expressions of ROCKs in the rat uterus 
might reduce the intensity of contraction, thereby facilitating the implantation of the embryos. 
The mRNA and protein expressions of RhoA and ROCKs were not always in parallel 
between pregnancy days 5-15, suggesting that the efficacy of translation from mRNA to 
protein is fluctuating. The protein expression of RhoA was unchanged from pregnancy day 5 
till day 22, while the ROCK proteins showed some significant alterations suggesting that, the 
active RhoA can contribute to cellular events without activation of Rho-kinases. The lower 
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expression of ROCKs may contribute to the maintenance of relative quiescence in the 
pregnant uterus. We detected that the mRNA and protein levels of RhoA and Rho-kinases 
were markedly up-regulated in the rat uterus at the onset of labour proposing their 
contribution to enhanced contractility and the initiation of labour. The higher expressions of 
RhoA and ROCKs in non-pregnant (oestrus) and delivering uteri can be related to an 
oestrogen plasma peak in rats. The oestradiol secretion are high in oestrus phase in the rat, 
while the level markedly decreases at night of 5th day of pregnancy and reaches the peak on 
the day of parturition (Yoshinaga et al., 1969; Downing et al., 1981). The RhoA expressed in 
both endometrial and myometrial tissues. Furthermore, high protein expression was measured 
in the endometrial samples on pregnancy day 22 and during parturition comparing to the non-
pregnant samples but remained unchanged in the myometrium suggesting that the alterations 
in RhoA expression are mainly the consequences of endometrial processes at the end of 
pregnancy. 
The cervix is a dense fibrous organ which acts as a mechanical barrier to keep the fetus inside 
the uterus during pregnancy. At the end of gestational period the cervical tissue is softensed 
and dilated (Chwalisz and Garfield, 1997) to facilitate the delivery. This process is called 
maturation, and regulated by several factors including the hormonal changes (Stjernholm et 
al., 1996) and prostaglandin amounts (Hertelendy and Zakar, 2004), the degradation of 
collagen network by the activation of matrix metalloproteinases (Ludmir and Sehdev, 2000). 
We measured that the mRNA level of RhoA slightly increased during pregnancy in rat cervix 
that followed a decrease at term. Interestingly, the protein expression of RhoA was 
significantly reduced on pregnancy day 20 and during delivery, but this alteration was not 
completely reflected the mRNA expression. In case of ROCK I and ROCK II, the expression 
levels sharply declined at term suggesting their impact on the final cervical ripening and 
delivery process. The decreased cervical resistance correlates to the low level of RhoA, which 
is concordant with the result that RhoA inactivation prevents collagen-I synthesis (Kondrikov 
et al., 2011) and contributes to the smooth muscle relaxation. Within 1 day after delivery, the 
RhoA and ROCK protein expressions had recovered to the level of non-pregnant level 
suggesting that the higher amount of RhoA/ROCK proteins may be important for the 
reconstruction of cervical tissue. Additionally, the RhoA-ROCK system is involved in 
apoptotic processes in several organs (e.g. kidney, liver, heart) (Wang et al., 2018; Ding et al, 
2016; Niermann et al., 2016). The apoptotic process contributes to cervical ripening at the end 
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of pregnancy (Hassan et al., 2006), thus this is another reason to investigate the RhoA-ROCK 
system in cervical ripening. 
For functional investigation of the roles of RhoA and ROCKs, we tested the effects of the 
RhoA inhibitor simvastatin and Rho-kinase inhibitors Y-27632 and fasudil on uterine 
contractility and cervical resistance. The hydroxy-methyl-glutaryl- coenzyme A (HMG-CoA) 
inhibitors (statins) were developed to inhibit the cholesterol synthesis (Tobert, 2003), but they 
have cholesterol-independent „pleiotropic” effects. Statins like simvastatin can inhibit the 
synthesis of isoprenoids, which are necessary for membrane translocation and activation of 
small GTPases RhoA (Wang et al., 2008; Tatsuta et al., 2003). It was previously reported that 
the inhibitor of RhoA caused relaxation in the anal sphincter (Patel and Rattan, 2007) and 
decreased the vascular contractility via increasing endothelial nitrogen monoxide production 
in rabbit artery (Shiga et al., 2005). Our in vitro organ bath study focused on the late-term 
(during parturition) and early postpartum (postpartum day 1) uteri in comparison with the 
non-pregnant uterus only, because our previous results showed that the most characteristic 
drug actions can be determined after day 18 of the gestation period (Domokos et al., 2017; 
Gál et al, 2009).  
We found that simvastatin relaxed the rat uterine contraction, although its action was not 
consequent on the expression of RhoA protein. The RhoA level was equivalently high during 
parturition and postpartum day 1, but the relaxing action of simvastatin both in maximum and 
IC50 value was the slowest on postpartum day 1 and much stronger during parturition. The 
RhoA expression level was low on day 22, while the simvastatin inhibitory action was the 
largest on that day. Interestingly, the intensity of the oxytocin-induced uterine contractions 
during parturition and on the first day of postpartum period was different, which might 
contribute to the different action of simvastatin. Furthermore, the relaxing action of 
simvastatin partially depends on its RhoA inhibitory property. It can be supported that the 
unprenylated Rho is able to interact with their effectors, but this interaction is less potent than 
with prenylated Rho (Turner et al., 2008).  
The cervical resistance was increased by simvastatin on pregnancy days 20 and 22, when the 
protein expression was low. The enhanced cervical resistance can be resulted by the 
pleiotropic effect of statins that is associated with the inhibition of the secretion of matrix 
metalloproteinases (MMPs) (Wong et al., 2001). MMPs play a major role in collagen network 
degradation (Luan et al., 2003) and collagen synthesis (Spinale, 2002; Strauss et al., 1996). 
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Although simvastatin was reported to decrease MMP-9 activity in human endothelial cells, 
this action was detected after 12 h of preincubation with the compound, only (Izidoro-Toledo 
et al., 2011). Ispanovic et al. (2008) reported that RhoA suppresses MMP-2 and MT1-MMP 
expression and MMP-2 activation. These suggest that simvastatin may have an RhoA 
independent effect in cervical tissue that leads to the increase in cervical resistance and seems 
unique in the cervix, because simvastatin acts rather as a relaxing than a contracting agent in 
vascular (Chen et al., 2016) and – as we proved – in myometrial smooth muscles.  
We also examined the effects of ROCK inhibitors on the uterine contractility. We have used 
non-selective ROCK inhibitors, fasudil, Y-27632, and RKI 1447. Y-27632 and fasudil are 
potent non-selective ROCKs inhibitors, they act as competitors against ATP to bind to the 
catalytic sites in enzymes (Asano et al., 1989; Ishizaki et al., 2000) resulting in smooth muscle 
relaxation. We combined the mRNA or protein expression data of ROCK I and ROCK II in 
order to provide information about the whole expressions of ROCKs to compare the actions 
of inhibitors to their target proteins. Fasudil had a strong inhibitory effect on the non-pregnant 
uterus, while it elicited moderate relaxation on 22 day pregnant, parturient and postpartum 
uterus. However, the IC50 values of fasudil were similar on each day and its action did not 
follow the expression levels of ROCKs. It can be explained that the effect of fasudil is not 
strictly attached to ROCK activity, it has non-specific inhibitory effects on other 
serine/threonine kinases such as MSK1, PRK2 (Davies et al., 2000). The actions of more 
specific ROCKs inhibitors Y- 27632 and RKI 1447 reflected the alteration of ROCKs 
expression. They had large relaxing effect on non-pregnant uteri and during parturition, when 
the expression levels of ROCKs were the highest. The maximum inhibitory effects of Y- 
27632 and RKI 1447 were weaker on pregnancy day 22 and postpartum day 1, when the 
ROCKs levels were also low. Interestingly, their IC50 values were not followed the alteration 
of target proteins expressions suggesting that both of ROCK I and II expressions together can 
contribute to the regulation of uterine contractility and correlate with the inhibitory effects of 
specific ROCK blockers. 
Y-27632 and fasudil decreased the resistance of 20-day pregnant cervices but had no 
significant effects for the resistance of 22-day pregnant samples. Fukushima et al. (2005) 
reported that fasudil suppresses the collagen secretion and increased the collagenase activity 
in hepatic stellate cells suggesting its contribution to the cervical action showes relaxant effect 
on vascular and myometrial smooth muscle (Shimomura et al., 2004). Li et al. (2016) found 
that Y-27632 inhibits the voltage dependent potassium (Kv) channels and reduces the muscle 
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tone in vascular smooth muscle. This ability might be associated with the cervical resistance 
decreasing effect of the drug, because Kv channel expressions have been confirmed in smooth 
muscle part of cervix (de Lera Ruiz and Kraus, 2015). But it was proved that Y-27632 has a 
collagen synthesis inhibitory effect (Ding et al., 2012), and its action can be detected after 30 
min of incubation (Yang et al., 2014). Its quick effect may play an important role in the 
alteration of cervical resistance found in our in vitro organ bath examinations after pre-
treatments with ROCK inhibitors. We hypothesized that ROCK inhibitors reduce the collagen 
concentration quickly during pregnancy, but they have no action on parturient cervical 
resistance because cervix loses its collagen content till labour. According of our results we 
suppose that the RhoA/ROCK signalling pathway may contribute to the cervical ripening, 
mainly in the final processes leading to delivery, and their sharp increase in post-partum 
period reveal their role in cervical remodelling process. 
We analysed the influences of some newly synthesized isoquinolines on the non-pregnant rat 
uterine contraction related to the ROCK activity as compared with action of fasudil and Y-
27632. It was known that isoquinolines relaxed the smooth muscles e.g. drotaverine 
hydrochloride reduces the duration of labour by affecting cervical dilation (Sharma et al., 
2001), while papaverine decreases the tonus and the contractile activity of smooth muscles 
(Huddart and Saad, 1980). Our results showes that 11 isoquinoline molecules had a lower IC50 
values on the oxytocin-induced uterine contraction in the non-pregnant rat, but their maximal 
inhibitory effects were weaker than those of both reference molecules. Papaverine had a 
stronger maximum inhibitory effect than Y-27632, while drotaverine had higher IC50 values 
than our reference compounds on non-pregnant uterine contractions. Papaverine and 
drotaverine have a non-selective phosphodiesterase inhibitory effect and are able to block the 
calcium channels, therefore their observed relaxing effects on uterine contraction may be less 
associated with the ROCK inhibitory properties. After the testing of the efficiency of the 
isoquinoline molecules for ROCK II activity, we found that the inhibitory actions of two 
molecules (218 and 852) were similar to that of Y-27632. We also tested their effect on day 
20 of pregnancy and during parturition and we found equal relaxing effect to the reference 
molecule, which is a significant development in comparison with non-pregnant results.  
 
 
 
40 
 
 
6. Summary  
Preterm birth is the major cause of neonatal morbidity and mortality. Despite the recent 
developments in perinatology and prenatal care, the mechanisms of preterm uterine 
contractility are still unknown It is a pharmacological challenge to find new effective 
therapeutic mechanisms, targets to reducing the preterm delivery rate and improving the 
perinatal outcome.  
Based on our results, we can conclude that: 
1. Normal pregnancy suppresses ROCKs in uterine tissue till parturition to maintain 
relaxed state of the uteri.  
2. The higher levels of ROCK in cervical tissues till delivery may contribute to closed 
position of cervix.  
3. A sharp increase of ROCKs in the uterus and the marked decrease in the cervix at the 
onset of labour may be a key element of enhanced contractility and the initiation of 
delivery with dilation of cervix.  
3.1. Y27632 had a large relaxing effect on non-pregnant uteri and during parturition, 
when the expression levels of ROCKs were the highest. 
3.2. Simvastatin enhanced the cervical resistance, therefore compounds with 
simvastatin-like action might be new drug candidates for preterm cervical 
ripening. 
4. The RhoA/Rho-kinase signal pathway can be a new target for the development of new 
tocolytic agenst, but the high specificity of RhoA and Rho-kinase inhibitors seems to 
be essential for the high efficacy of normal uterine and cervical function. The 
isoquinoline structure can be promising for the development of new and effective 
inhibitors of ROCKs. 
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